Market Closed -
Other stock markets
|
After market 03:47:35 pm | |||
79.4 EUR | -0.06% | 79.22 | -0.22% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.89% | 4.39B | |
+24.72% | 672B | |
+24.08% | 550B | |
-5.89% | 351B | |
+15.55% | 317B | |
+7.21% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.78% | 144B | |
-6.58% | 141B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi S A : Farmacéuticos Rovi FY20 Profit Climbs 55%; Dividend Raised